Defeating cancer together: our policy priorities
We believe there are three areas the Government could prioritise to enable cancer research in academic institutions to thrive, and help us on our mission to continue making the discoveries that defeat cancer.
"We need the Government to use all available policy levers to support the sector and help cancer research in UK academic institutions thrive."
- Professor Kristian Helin, Chief Executive, The Institute of Cancer Research
"100 days in - it is vital that this new Parliament comes together to prioritise cancer research. For all of us affected by cancer, research is where hope starts, Parliament can help catalyse this hope"
- Sue Duncombe, Cancer Patient Advocate
Advocacy blog posts
The Charity Research Support Fund: An overlooked, and neglected, lifeline for UK science
Ollie Richards, Advocacy Manager at the ICR, explores how a critical element of the Government's research funding – the Charity Research Support Fund – could be reformed to help support more specialist institutions and universities to do life-saving research.
100 days in – what do we need from the Government to enable cancer research to thrive?
We’re now 100 days into the new Government and the ICR’s Advocacy Manager, Ollie Richards, outlines what academic institutions need the Government to prioritise to help us on our mission to continue making the discoveries that defeat cancer.
Latest ICR News
New trial design could improve early-stage cancer studies involving CAR-T therapies
Researchers have developed a new statistical approach that could help improve how early-stage cancer trials identify the safest and most effective doses of advanced therapies, such as CAR-T therapy.
Researchers develop gene-editing platform to systematically decode histone function in mammalian cells
Scientists have developed a powerful new gene-editing platform that allows them, for the first time, to systematically test the function of key proteins in mammalian cells.
New clinical trial design could improve dose selection, maximising treatment efficacy and safety
Researchers have developed a new approach to help determine the optimal dose of cancer drugs, aiming to make early-stage clinical trials more transparent and better aligned with patient needs.